AboutEffRx Pharmaceuticals SA
Lean and Agile Integrated Market-Oriented Biopharma Focused on Niche Therapeutics in Europe
EffRx Pharmaceuticals is a commercial-stage pharmaceutical company focused on the late-stage development and commercialization of prescription medications for niche and orphan indications. The business model is centered around providing superior clinical and commercial value propositions for physicians, payers and patients.
EffRx pro-actively seeks in-licensing opportunities for Europe in niche therapeutic areas, with a primary interest in rare diseases, where one of its pipeline assets has received an orphan drug designation (ODD) from the FDA in US.
EffRx’s go-to-market competence is proven by the development, launch and lucrative expansion of Binosto® in a highly competitive European market. Our lead commercialized product, Binosto® for the treatment of osteoporosis, is marketed in the US as well as selected European and Asian countries.
Business Strategy
EffRx Pharmaceuticals is a lean and agile, integrated, market-oriented biopharma focused on niche therapeutics in Europe and in Switzerland. Our business strategy focuses on successfully shaping the late development and launch of therapeutics for patients suffering from niche and rare diseases.
We tailor the late clinical and regulatory development of niche and orphan medicines to build powerful, differentiated launch propositions, to ensure accelerated market entry and to maximize long term market opportunities.
Our business model centers around providing superior clinical and commercial value propositions for physicians, payers and patients.
Our strategy is to be the preferred EU/Swiss partner and accelerator for late clinical development, approval and valorization of niche/orphan prescription medicines.
Additionally, EffRx Pharmaceuticals has a very effective, lean team with proven cross-functional competencies in:
EffRx actively seeks collaboration opportunities with small to mid-sized biopharmaceutical companies not having an EU/Swiss set-up and looking to commercialize their medicines in Europe/Switzerland.
